Shots:

• Carna to receive $2.0M up front, ~$258.0M success-based development, regulatory, and sales & is also eligible to receive a royalty of up to 10% of net sales
• Brickell gets an exclusive global right to develop and commercialize Carna’s portfolio of STING antagonists & will lead the future development activities and expenses related to the STING inhibitor platform
• The agreement boosts Brickell’s pipeline in immunology and inflammation and uses its drug development capabilities to advance Carna’s STING inhibitors BBI-10 for the treatment of autoimmune and inflammatory diseases. BBI-10 showed dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies

Ref: Globe Newswire | Image: BrickellBio